The PennZone

  • Home
  • Entertainment
  • Marketing
  • Music
  • Non-profit
  • Books
  • Artificial Intelligence
  • Education
  • Automotive

Olympus Acquires Veran Medical Technologies, Inc.
The PennZone/10102444

Trending...
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
CENTER VALLEY, Pa. and TOKYO, Dec. 30, 2020 /PRNewswire/ -- Olympus Corporation today announced that it has finalized the acquisition of Veran Medical Technologies, Inc. (VMT), a leading provider of advanced medical devices specializing in interventional pulmonology, following the definitive agreement the two companies signed December 4, 2020. With this acquisition by Olympus subsidiary Olympus Corporation of the Americas (OCA), Olympus gains VMT's global sales network, marketing, manufacturing, R&D, and other functions to expand the Olympus respiratory product portfolio.

Lung cancer is the leading cause of cancer-related deaths globally.1 With increased awareness and more lung cancer screenings using low-dose computed tomography (CT), the need for definitive diagnosis of lesions in the peripheral regions of the lungs by tissue biopsy is expected to increase. VMT's SPiN Thoracic Navigation System® and related devices are specifically designed to help physicians navigate to, localize, and sample peripheral pulmonary lesions. Together with the existing Olympus respiratory portfolio that includes radial endobronchial ultrasound (EBUS) and thin bronchoscopes, VMT's navigational system and related devices provide a powerful combination of imaging, access and precision for pulmonologists seeking to diagnose and determine the stage of a patient's lung cancer.

More on The PennZone
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
  • CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
  • NaturismRE expands international research programme with Health & Wellbeing Survey
  • L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach
  • LATO AI Solidifies Future in Pittsburgh with North Shore Headquarters

"We are very excited about the synergies this acquisition creates. With the deal now closed, as one company we are able to combine Olympus' expertise and clinical history in minimally invasive technology with the innovation in navigation systems of Veran Medical Technology to improve workflow and patient care in lung cancer," said Lynn Ray, Vice President and General Manager of the Global Respiratory Business Unit for Olympus Corporation. "Olympus is committed to providing the medical community with the best tools possible to use in their fight against cancer. With the advent of EBUS-guided transbronchial needle aspiration (EBUS-TBNA) in 2004, Olympus brought patients the benefit of more accurate diagnosis and staging, to improve patient outcomes and care. We are thrilled to be at the forefront of development in this rapidly evolving area of respiratory care."

The acquisition will provide immediate incremental revenue and an experienced sales team within the U.S. market. VMT's advanced and proven navigation technology, together with Olympus' respiratory portfolio, strengthens and enhances Olympus' global position as a medical technology innovator.

As part of its current Corporate Strategy, Olympus vowed to "focus and scale" its Therapeutic solutions Division (TSD). To accelerate the process and provide greater agility, Olympus made OCA the TSD headquarters, recognizing the significant growth opportunities in North America. Olympus also identified three core medical fields to prioritize and has since focused on gastroenterological endotherapy devices, urological devices, and respiratory devices. The VMT acquisition is centered on respiratory devices and will position Olympus as a leader in this field.

More on The PennZone
  • Re:InvestorHub Launches the First AI-Powered Operating System Built for Real Estate Investors
  • Nadi Plumbing Leads Charlotte in Private Fire Hydrant Services, Eyes Regional Expansion
  • Obsolete Industrial Expands Its Membership
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man

For additional information, please refer to our corporate disclosure, "Notice regarding acquisition of Veran Medical Technologies, Inc. in the United States."

(available at: https://www.olympus-global.com/news/ir/2020/)

1 WHO data:  https://www.who.int/news-room/fact-sheets/detail/cancer

About Olympus' Therapeutic Solutions Division
In its Therapeutic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Starting with its early contributions to the development of the polypectomy snare, Olympus' Therapeutic Solutions portfolio has grown to include an array of surgical energy devices and a wide range of instruments to help prevent, detect, and treat disease. For more information, visit www.olympus-global.com.

SOURCE Olympus

Related Links

http://www.olympus.com/
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • Slotozilla Reports Strong Growth in Q2 2026
  • Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
  • Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
  • Flexible Plan Investments Names Carl Resnick President
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
  • Sharon Pinkenson Chosen as Philly Girl Top 40 Winner
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
  • Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
  • GGILabs Expands Local SEO Services to Help Businesses Compete in AI-Driven Search
  • Sara Viteri, Turnstone Creative Senior Producer, Named to Lehigh Valley Business' Forty Under 40
  • Boyertown Mechanic Travels to Nashville to Learn How AI Is Changing Auto Repair
  • Colonial Nissan Earns Capital One Top Performing Dealership Award

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 711
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 108
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH - 103
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Crossroads4Hope Announces The Lipschutz Women's Fund

Similar on PennZone

  • New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
  • Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • Slotozilla Reports Strong Growth in Q2 2026
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us